OBJECTIVES: The in vivo inflammatory effects of the Bacillus anthracis cell wall are unknown. We therefore investigated these effects in rats and, for comparison, those of known inflammatory stimulants, Staphylococcus aureus cell wall or lipopolysaccharide (LPS). METHOD AND RESULTS: Sprague-Dawley rats (n = 103) were challenged with increasing B. anthracis cell wall doses (10, 20, 40, 80, or 160 mg/kg) or diluent (control) as a bolus or 24-h infusion. The three highest bolus doses were lethal (20-64% lethality rates) as were the two highest infused doses (13% with each). Comparisons among lethal or nonlethal doses on other measured parameters were not significantly different, and these were combined for analysis. Over the 24 h after challenge initiation with lethal bolus or infusion, compared to controls, ten inflammatory cytokines and NO levels were increased and circulating neutrophils and platelets decreased (P <or= 0.05). Changes with lethal doses were greater than changes with nonlethal doses (P <or= 0.01). Lethal bolus or infusion doses produced hypotension or hypoxemia, respectively (P <or= 0.05). The effects with B. anthracis cell wall were similar to those of S. aureus cell wall or LPS. However, paradoxically administration of B. anthracis cell wall or LPS decreased the lethality of concurrently administered B. anthracis lethal toxin (P < 0.0001 and 0.04, respectively). CONCLUSION: B. anthracis cell wall has the potential to produce inflammatory injury during anthrax infection clinically. However, understanding why cell wall or LPS paradoxically reduced lethality with lethal toxin may help understand this toxin's pathogenic effects.
OBJECTIVES: The in vivo inflammatory effects of the Bacillus anthracis cell wall are unknown. We therefore investigated these effects in rats and, for comparison, those of known inflammatory stimulants, Staphylococcus aureus cell wall or lipopolysaccharide (LPS). METHOD AND RESULTS:Sprague-Dawley rats (n = 103) were challenged with increasing B. anthracis cell wall doses (10, 20, 40, 80, or 160 mg/kg) or diluent (control) as a bolus or 24-h infusion. The three highest bolus doses were lethal (20-64% lethality rates) as were the two highest infused doses (13% with each). Comparisons among lethal or nonlethal doses on other measured parameters were not significantly different, and these were combined for analysis. Over the 24 h after challenge initiation with lethal bolus or infusion, compared to controls, ten inflammatory cytokines and NO levels were increased and circulating neutrophils and platelets decreased (P <or= 0.05). Changes with lethal doses were greater than changes with nonlethal doses (P <or= 0.01). Lethal bolus or infusion doses produced hypotension or hypoxemia, respectively (P <or= 0.05). The effects with B. anthracis cell wall were similar to those of S. aureus cell wall or LPS. However, paradoxically administration of B. anthracis cell wall or LPS decreased the lethality of concurrently administered B. anthracis lethal toxin (P < 0.0001 and 0.04, respectively). CONCLUSION:B. anthracis cell wall has the potential to produce inflammatory injury during anthraxinfection clinically. However, understanding why cell wall or LPS paradoxically reduced lethality with lethal toxin may help understand this toxin's pathogenic effects.
Authors: Xizhong Cui; Yan Li; Mahtab Moayeri; Gil H Choi; G M Subramanian; Xuemei Li; Michael Haley; Yvonne Fitz; Jing Feng; Steven M Banks; Stephen H Leppla; Peter Q Eichacker Journal: J Infect Dis Date: 2004-12-22 Impact factor: 5.226
Authors: Serguei G Popov; Rafael Villasmil; Jessica Bernardi; Edith Grene; Jennifer Cardwell; Taissia Popova; Aiguo Wu; Darya Alibek; Charles Bailey; Ken Alibek Journal: FEBS Lett Date: 2002-09-11 Impact factor: 4.124
Authors: Jon-Erik C Holty; Dena M Bravata; Hau Liu; Richard A Olshen; Kathryn M McDonald; Douglas K Owens Journal: Ann Intern Med Date: 2006-02-21 Impact factor: 25.391
Authors: Martha Triantafilou; Ahmed Uddin; Sebastien Maher; Nicholas Charalambous; Thomas S C Hamm; Ahmad Alsumaiti; Kathy Triantafilou Journal: Cell Microbiol Date: 2007-07-26 Impact factor: 3.715
Authors: Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti Journal: J Biol Chem Date: 2003-01-13 Impact factor: 5.157
Authors: Daniel A Sweeney; Caitlin W Hicks; Xizhong Cui; Yan Li; Peter Q Eichacker Journal: Am J Respir Crit Care Med Date: 2011-08-18 Impact factor: 21.405
Authors: Amisha V Barochia; Xizhong Cui; Junfeng Sun; Yan Li; Steven B Solomon; Thi-Sau Migone; G Mani Subramanian; Sally D Bolmer; Peter Q Eichacker Journal: J Infect Dis Date: 2012-01-05 Impact factor: 5.226
Authors: Daniel A Sweeney; Xizhong Cui; Steven B Solomon; David A Vitberg; Thi S Migone; Dara Scher; Robert L Danner; Charles Natanson; G Mani Subramanian; Peter Q Eichacker Journal: J Infect Dis Date: 2010-11-10 Impact factor: 5.226
Authors: Kenneth Mark Coggeshall; Florea Lupu; Jimmy Ballard; Jordan P Metcalf; Judith A James; Darise Farris; Shinichiro Kurosawa Journal: J Cell Mol Med Date: 2013-06-07 Impact factor: 5.310